Guselkumab: A Review in Moderate to Severe Plaque Psoriasis-Reference-Cited by-同舟云学术

Guselkumab: A Review in Moderate to Severe Plaque Psoriasis

Published:2018-11-22 Issue:6 Volume:19 Page:907-918
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Al-Salama Zaina T.,Scott Lesley J

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

http://link.springer.com/article/10.1007/s40257-018-0406-1/fulltext.html

Reference40 articles.

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.

2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–74.

3. National Institute for Health and Care Excellence (NICE). Psoriasis: assessment and management. 2012. https://www.nice.org.uk/guidance/cg153 . Accessed 23 Oct 2018.

4. Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–40.

5. European Medicines Agency. Summary of product characteristics: tremfya 100 mg solution for injection. 2017. http://www.ema.europa.eu/ . Accessed 23 Oct 2018.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness;Cureus;2023-12-31

2. Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?;European Journal of Pharmacology;2022-08

3. Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis;International Journal of Molecular Sciences;2022-05-06

4. What Can IBD Specialists Learn from IL-23 Trials in Dermatology?;Journal of Crohn's and Colitis;2022-04-01

5. Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen;Pädiatrische Rheumatologie;2022